GILD Gilead Sciences Inc.

63.14
+0.27  (+0%)
Previous Close 62.87
Open 63.41
Price To Book 3.54
Market Cap 79,963,999,070
Shares 1,266,455,481
Volume 7,593,275
Short Ratio
Av. Daily Volume 6,261,536

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 trial to be initiated in 2018.
Yescarta (Axicabtagene Ciloleucel) and Utomilumab (PF-05082566)
Large B-Cell Lymphoma
Phase 3 trial did not meet primary endpoint - February 11, 2019.
Selonsertib (GS-4997) - STELLAR 4
Nonalcoholic steatohepatitis (NASH)
Phase 2 enrollment completed 1Q 2018.
Selonsertib (GS-4997)
Alcoholic Hepatitis
Phase 2 data due 3Q 2019.
Filgotinib and GS-9876
Sjogren’s syndrome
Phase 3 enrolment to be completed 2H 2020.
Cilofexor (GS-9674)
Primary sclerosing cholangitis
Phase 2 data released November 9, 2018.
GS-9674
Primary biliary cholangitis
Phase 2 trial to complete enrolment 3Q 2019.
GS-5734
Ebola
sNDA filed April 5, 2019. Likely PDUFA date under priority review of October 4, 2019.
F/TAF (Descovy)
Pre-exposure prophylaxis
Phase 2 data due 1H 2020.
Axicabtagene ciloleucel - (ZUMA-5)
Indolent B-Cell Non-Hodgkin Lymphoma
Phase 2 data due 3Q 2019.
Filgotinib and GS-9876
Cutaneous lupus erythematosus (CLE)
Phase 3 initiated August 2016
Filgotinib - FINCH 4
Rheumatoid arthritis (RA)
Phase 3 data released March 28, 2019 - primary endpoint met.
Filgotinib - FINCH 3
Rheumatoid arthritis (RA)
Phase 3 data released September 11, 2018. Endpoints met.
Filgotinib - FINCH 2
Rheumatoid arthritis (RA)
Phase 3 trial to be initiated 1H 2020.
Filgotinib - TORTUGA
Ankylosing spondylitis
Phase 3 trial to be initiated 4Q 2019.
Filgotinib - EQUATOR
Psoriatic arthritis
Phase 3 futility analysis 3Q 2017. Trial to continue.
Andecaliximab GS-5745
Gastric Cancer
Approved February 7, 2018.
Bictegravir/F/TAF
HIV
Phase 2 data 4Q 2018.
GS-9674
Nonalcoholic steatohepatitis (NASH)
Phase 3 data April 25, 2019 did not meet primary endpoint.
Selonsertib (GS-4997) - STELLAR 3
Nonalcoholic steatohepatitis (NASH)
Phase 2 data released October 24, 2017. Positive high dose data, low dose negative.
GS-0976
Nonalcoholic steatohepatitis (NASH)
Approval announced July 18, 2017.
Vosevi (Sofosbuvir/Velpatasvir/Voxilaprevir)
Hepatitis C virus (HCV)
Phase 2 ongoing.
Entospletinib
Chronic Graft Versus Host Disease (cGVHD)
Phase 3 data due 2Q 2020.
Filgotinib - SELECTION
Ulcerative colitis
Phase 3 enrolment to be completed 3Q 2020.
Filgotinib - DIVERSITY
Crohn’s disease
NDA filing due 3Q 2019.
Filgotinib
Rheumatoid arthritis (RA)
Phase 2 data due 3Q 2019.
Axicabtagene ciloleucel - (ZUMA-2)
Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL) - cancer
Phase 2 pivotal trial enrolment to be completed 4Q 2019.
Axicabtagene ciloleucel - (ZUMA-3)
Adult patients with r/r ALL - cancer
Phase 1/2 data released 2Q 2019.
Axicabtagene ciloleucel - (ZUMA-4)
Pediatric and young adult patients with r/r ALL - cancer
2-year data at ASH 2018 noted 39% of patients were in an ongoing response. OS not yet reached.
Yescarta (axicabtagene ciloleucel)
Refractory Non-Hodgkin's Lymphoma (NHL) - cancer
Phase 1/2 data due 1H 2020.
Axicabtagene ciloleucel (ZUMA-6)
Refractory diffuse large B-cell lymphoma (DLBCL)
Phase 1 data due 4Q 2019.
Axicabtagene ciloleucel (ZUMA-8)
Chronic lymphocytic leukemia (CLL)
Phase 2 data due 3Q 2019.
GS-9131
HIV
Phase 3 enrollment to be completed 4Q 2019.
Axicabtagene ciloleucel (ZUMA-7)
Refractory diffuse large B-cell lymphoma (DLBCL)
Phase 2b 48-week data due 4Q 2019.
Cilofexor (GS-9674) and firsocostat (GS-0976) - ATLAS
Nonalcoholic steatohepatitis (NASH)
Phase 3 trial to be initiated 3Q 2019.
Selonsertib (GS-4997)
Diabetic kidney disease
Phase 1 initial data due 1H 2020.
Axicabtagene ciloleucel - KTE-C19 (ZUMA-11)
Phase 2 data due 4Q 2019.
GS-9688
HBV
Phase 2 trial to be initiated 3Q 2019.
Axicabtagene ciloleucel and rituximab/lenalidomide (ZUMA-14)
Phase 2 enrolment to be completed 1H 2020.
Axicabtagene ciloleucel - (ZUMA-12)
Diffuse Large B-Cell Lymphoma (DLBCL)
Phase 2 trial to be initiated 4Q 2019.
GS-4875
Ulcerative Colitis

Latest News

  1. Gilead's (GILD) Filgotinib MAA for RA Accepted in Europe
  2. Frozen assets: How a startup wants to cryobank your cells to fight cancer in the future
  3. European Medicines Agency Validates Marketing Application for Filgotinib for the Treatment of Rheumatoid Arthritis
  4. Québec Provides Access to Biktarvy® for the Treatment of HIV
  5. Biotech Stock Roundup: Amgen's Enbrel Patent Win, AMRN's Setback & More
  6. Zacks Industry Outlook Highlights: Gilead Sciences, Regeneron Pharmaceuticals, Amgen, Vertex Pharmaceuticals and Alexion Pharmaceuticals
  7. Mergers & Acquisitions Take Center Stage in Biotech Industry
  8. Is Gilead Sciences (GILD) a Great Stock for Value Investors?
  9. What Kind Of Investor Owns Most Of Gilead Sciences, Inc. (NASDAQ:GILD)?
  10. 3 Big Stock Charts for Monday: Xilinx, News Corp and Gilead Sciences
  11. 3 Embarrassingly Cheap Dividend Stocks
  12. Nektar (NKTR) Q2 Earnings Beat Estimates, Revenues Miss
  13. Agenus (AGEN) Q2 Earnings Miss Estimates, Revenues Beat
  14. Novo Nordisk (NVO) Q2 Earnings & Revenues Beat Estimates
  15. Gilead's HIV drug Biktarvy approved in China
  16. China National Medical Products Administration Approves Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) for Treatment of HIV-1 Infection
  17. Gilead Stock Is Among The Biggest Biotech Stocks — But Should You Buy It?
  18. Intercept (ICPT) Q2 Earnings & Sales Beat, NASH in Focus
  19. Medicare to cover expensive cancer cell therapies
  20. Gilead Sciences Statement on U.S. Food and Drug Administration Advisory Committee’s Recommendation on Descovy for PrEP™